FDA Approves the First US Plasmid-DNA Immunotherapy
The FDA granted accelerated approval to Voceryq for adults with recurrent respiratory papillomatosis. The plasmid-DNA immunotherapy reduced surgery frequency in a small open-label trial, but confirmatory studies must still verify durable clinical benefit.
The US Food and Drug Administration has granted accelerated approval to Voceryq, the first plasmid-DNA immunotherapy approved in the country. The treatment is intended for adults with recurrent respiratory papillomatosis, a rare HPV-driven disease that repeatedly produces growths in the airway and often forces patients into years of surgery.
The 30-second summary
- What happened? The FDA approved Voceryq for adults with recurrent respiratory papillomatosis.
- Why does it matter? It trains immunity against HPV proteins and aims to reduce repeated operations instead of only removing each new growth.
- What is the catch? Approval is accelerated and based on an intermediate endpoint in a small, open-label trial. Confirmatory evidence is still required.
Key Number: Seven of 26 patients with at least three baseline surgeries needed no surgical intervention during the first year after treatment.
The disease can create a cycle of surgery
Recurrent respiratory papillomatosis is usually caused by HPV types 6 or 11. Wart-like papillomas grow most often around the vocal cords, causing hoarseness and sometimes obstructing breathing. Surgery can clear the airway, but it does not remove persistent HPV from the tissue, so growths can return.
Voceryq delivers two bacterial plasmids. One carries instructions for selected HPV proteins; the other encodes the immune-stimulating molecule IL-12. The dose is injected into muscle and brief electrical pulses temporarily open pores in cell membranes, a process called electroporation that helps the DNA enter cells.
The trial measured fewer operations
The FDA evaluated an open-label, multicenter study of 32 adults who had required at least two surgeries during the previous year. Among 26 patients with at least three baseline surgeries, 27% avoided surgery during the year after treatment. The broader study reported reductions in surgical frequency, but it had no randomized placebo group.
The approach is another example of genetic instructions being used to direct immunity, although it differs from the personalized mRNA cancer vaccine covered by NewTqnia. Voceryq uses plasmid DNA against viral proteins shared by HPV-driven disease, rather than a patient-specific list of tumor mutations.
Before we overstate the result
Accelerated approval does not mean the FDA has complete evidence of long-term clinical benefit. The agency accepted reduced surgery as an intermediate endpoint reasonably likely to predict benefit, and the manufacturer must conduct post-approval trials. The small uncontrolled study also cannot fully separate treatment effects from changes in disease course or clinical practice.
Safety and the next requirement
Common reported reactions included injection-site effects, headache, fatigue, high blood pressure, nausea and dizziness. Electroporation can cause brief muscle contractions, pain or bleeding at the injection site. The decisive next step is confirmatory testing that establishes whether fewer surgeries and durable disease control persist in a broader patient population.
Verified topics and entities
Sources and citations3 sources
External references used to support the reporting in this article.
Published by
NewTqnia Health Desk
An institutional editorial team within NewTqnia
